aztreonam has been researched along with cefaclor anhydrous in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Miriagou, V; Papagiannitsis, CC; Tzelepi, E; Tzouvelekis, LS | 1 |
| Arakawa, Y; Ishikawa, K; Nagano, N; Nagano, Y; Wachino, J | 1 |
| Miriagou, V; Papagiannitsis, CC; Tzouvelekis, LS | 1 |
| Kotsakis, SD; Miriagou, V; Papagiannitsis, CC; Tzelepi, E; Tzouvelekis, LS | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Kotsakis, SD; Legakis, NJ; Miriagou, V; Papagiannitsis, CC; Tzelepi, E; Tzouvelekis, LS | 1 |
| Campos, J; Carrilero, L; Escudero, JA; Garcia-Cobos, S; Gonzalez-Zorn, B; Gutierrez, B; Hidalgo, L; San Millan, A | 1 |
| Bommareddy, A; Gionfriddo, MR; Heindel, GA; Mukhija, P; Vanwert, AL; Witkowski, S; Wolman, AT | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Barry, AL; Fuchs, PC; Jones, RN | 1 |
| Aoki, K; Hayashi, M; Kawano, Y; Noma, T; Shikishima, Y; Yoshizawa, I | 1 |
1 review(s) available for aztreonam and cefaclor anhydrous
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
11 other study(ies) available for aztreonam and cefaclor anhydrous
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli.
Topics: Anti-Bacterial Agents; Cephalosporinase; Culture Media; DNA Primers; Drug Resistance, Bacterial; Escherichia coli; Kinetics; Models, Molecular; Molecular Sequence Data; Plasmids; Reverse Transcriptase Polymerase Chain Reaction; Spectrophotometry, Ultraviolet | 2007 |
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
Topics: Amino Acid Sequence; beta-Lactamases; Blotting, Southern; Ceftazidime; Cephalosporins; Kinetics; Microbial Sensitivity Tests; Molecular Sequence Data; Polymerase Chain Reaction; Sequence Homology, Amino Acid; Shigella sonnei | 2009 |
Relative strengths of the class 1 integron promoter hybrid 2 and the combinations of strong and hybrid 1 with an active p2 promoter.
Topics: beta-Lactamases; beta-Lactams; Integrons; Microbial Sensitivity Tests; Promoter Regions, Genetic; Pseudomonas aeruginosa | 2009 |
Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase.
Topics: Aztreonam; beta-Lactamases; beta-Lactams; Ceftazidime; Cephalosporins; Escherichia coli Proteins; Protein Binding; Protein Structure, Secondary | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactamases; beta-Lactams; Cephalosporins; Genetic Variation; Humans; Integrons; Microbial Sensitivity Tests; Molecular Sequence Data; Pseudomonas aeruginosa; Pseudomonas Infections; Sequence Analysis, DNA | 2010 |
Haemophilus influenzae clinical isolates with plasmid pB1000 bearing blaROB-1: fitness cost and interspecies dissemination.
Topics: Animals; beta-Lactamases; Cefaclor; Conjugation, Genetic; Drug Resistance, Bacterial; Haemophilus Infections; Haemophilus influenzae; Humans; Molecular Epidemiology; Molecular Sequence Data; Pasteurella multocida; Plasmids; Replicon; Spain; Species Specificity; Transformation, Genetic | 2010 |
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
Topics: Animals; Anti-Bacterial Agents; beta-Lactams; Biological Transport; Cell Line, Transformed; Humans; Mice; Organic Anion Transport Protein 1; Organic Anion Transporters, Sodium-Independent; Solubility; Structure-Activity Relationship | 2013 |
In vitro antimicrobial activity of tigemonam, a new orally administered monobactam.
Topics: Aztreonam; Bacteria; beta-Lactamases; Cefaclor; Drug Combinations; Hydrolysis; Microbial Sensitivity Tests; Monobactams; Sulfamethoxazole; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination | 1988 |
A comparative investigation of the restorative effects of roxithromycin on neutrophil activities.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Aztreonam; Blood Bactericidal Activity; Cefaclor; Cephalosporins; Child; Disabled Persons; Drug Interactions; Female; Flow Cytometry; Humans; Hydrogen Peroxide; Macrophage-1 Antigen; Male; Monobactams; Neutrophils; Ofloxacin; Phagocytosis; Roxithromycin | 1998 |